Cefepime–Taniborbactam: A Possible New Addition to the Treatment Arsenal for Complicated Urinary Tract Infection

In a randomized trial involving patients with complicated UTI (including acute pyelonephritis), cefepime–taniborbactam was superior to meropenem.

While cefepime has been a cornerstone in the management of healthcare-related infections such as urinary tract infections (UTIs), escalating antimicrobial resistance has eroded this agent's reliability in certain clinical settings. Taniborbactam is a broad-spectrum beta-lactamase inhibitor capable of inhibiting Ambler class A–D enzymes, restoring the activity of cefepime against multidrug-resistant gram-negative rods (MDR GNR), including carbapenem-resistant Enterobacterales species and Pseudomonas aeruginosa. In the CERTAIN-1 study — a phase 3 trial comparing cefepime–taniborbactam to meropenem in adults with complicated UTI (cUTI) or acute pyelonephritis — 661 patients were randomized 2:1 to cefepime–taniborbactam or meropenem for 7 days …

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases

Cefepime–Taniborbactam: A Possible New Addition to the Treatment Arsenal for Complicated Urinary Tract Infection

Topics

Reviewing Author